Clinical Trials Browser

OTHER × Hemangiosarcoma × regorafenib × Clear all

Pathologic Complete Response, Bone Neoplasms, Chondrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Patient Compliance, Sarcoma, Ewing, Osteosarcoma, Histiocytoma, Malignant Fibrous

NCT02048722 2022-04-25

Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

Phase 2 Completed

31 enrolled 15 charts

Sarcoma

Hemangiosarcoma, Sarcoma

Clinical Trials

REGOSTA

Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma